Development of bio-marine products.

  EGM January 4th 2021 

  Marine Conference  November 25th 2020

   EGM  October 16th 2020

  New Board August 20th 2020

New office, Oslo.  August 1st 2020

AGM 2020.  June 24th 2020 

   Update BlueBio.  June 9th 2020 

 

Regenics AS is a private Norwegian biotechnology company based in Oslo. We develop, licence and distribute our marine wound devices using therapeutically active bioctives from unfertilized salmon roe. Final development of devices for US/EU registration is scheduled for 2023-2024.

Wound Healing - Skin diseases

Regenics is developing several products for therapeutic skin applications. The most advanced is COLLEX®, a 3D-bioprinted wound patch and VERNEX® spray for wound healing. 

Vernex® - medical device for wound healing

Regenics develops medical devices for US, EU and Asian markets. Regenics bioactives purified from salmon roe have pluripotent stem cell resembling effects that incresee the rate of wound helaing. Collex® is a 3D-bioprinted first in class wound patch. Vernex® is a wound spray for larger wounds. WoundClear® is an enzyme under development for wound debridement.

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.